HilleVax - About the company
HilleVax is a public company based in Boston (United States), founded in 2021 by . It operates as a Developer of a vaccine for norovirus infection. HilleVax has raised $135M in funding from Frazier Healthcare Partners. The company has 79 active competitors, including 22 funded and 18 that have exited. Its top competitors include companies like Dynavax, Savara Pharma and VBI Vaccines.
Company Details
Developer of a vaccine for norovirus infection. The lead candidate HIL-214 is a norovirus bivalent GI.1/GII.4 virus-like particle vaccine indicated for active immunization for the prevention of acute gastroenteritis caused by norovirus.
- Website
- Social
- Email ID
- @hillevax.com
- Phone Number
- +1
Key Metrics
Founded Year
2021
Location
Boston, United States
Stage
Public
Total Funding
in 1 round
Latest Funding Round
Investors
Ranked
4th among
Employee Count
as on Dec 31, 2022
Similar Companies
Dynavax &
Exit Details
Public
Legal entities associated with HilleVax
HilleVax is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
CIN: 1888012 United States, Deadpooled | Mar 24, 2020 | - | - | - |
CIN: 85-0545060 United States, Active | Mar 24, 2020 | - | 62 (as on Dec 31, 2022) | - |
Get your free copy of HilleVax's company profile
HilleVax's funding and investors
HilleVax has raised a total funding of $135M over 1 round. Its latest funding round was a Series D round on Sep 08, 2021 for $135M. 13 investors participated in its latest round, lead by Frazier Healthcare Partners.
HilleVax has 13 institutional investors including Frazier Healthcare Partners, Abingworth and Deerfield.
Here is the list of recent funding rounds of HilleVax:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Sep 08, 2021 | $135M | Series D | 8880292 | 1603961 |
Access funding benchmarks and valuations. Sign up today!View details of HilleVax's funding rounds and investors
HilleVax's founders and board of directors
The founders of HilleVax is .
Here are the details of HilleVax's key team members:
- : Co-Founder of HilleVax and founder of , Phathom Pharmaceuticals and Incline Therapeutics.
View details of
HilleVax's employee count trend
HilleVax has 62 employees as of Dec 22. Here is HilleVax's employee count trend over the years:
Uncover HilleVax's growth story! Sign up today!
Access 秘密研究所 on any website
Our Google Chrome extension lets you view company details while browsing their websites
HilleVax's Competitors and alternates
Top competitors of HilleVax include Dynavax, Savara Pharma and VBI Vaccines. Here is the list of Top 10 competitors of HilleVax, ranked by 秘密研究所 score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | 秘密研究所 Score |
|---|---|---|---|---|---|
1st | Dynavax 1996, Berkeley (United States), Public | Developer of products to prevent and treat infectious and inflammatory diseases and cancer | $73.9M | 72/100 | |
2nd | Savara Pharma 2008, Austin (United States), Public | Developer of therapeutics for rare respiratory diseases | $67.8M | Hercules Capital, EcoR1听&补尘辫;听 | 63/100 |
3rd | VBI Vaccines 2001, Cambridge (United States), Public | Developer of vaccines for the treatment of infectious diseases | $65.1M | Perceptive Advisors, 5AM Ventures听&补尘辫;听 | 61/100 |
4th |  2021, Boston (United States), Public | Developer of a vaccine for norovirus infection | $135M | 59/100 | |
5th | Precigen 1998, Germantown (United States), Public | Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases | $234M | 59/100 | |
6th | Developer of vaccines against multiple infectious diseases | - | Vivo Capital, CDH听&补尘辫;听 | 56/100 | |
7th | Developer of vaccines for infectious diseases (merged with Vivalis {France} to form Valneva in 2012) | $78.6M | 54/100 | ||
8th | Inimmune 2016, Missoula (United States), Series A | Integrated clinical developmental services to treat food allergy, allergic rhinitis, and auto-immune disorders | $22M | 53/100 | |
9th |  Relief Therapeutics 2013, Geneva (Switzerland), Public | Developer of drugs for treating pulmonary and infectious diseases | $2.75M | NewH2听&补尘辫;听 | 52/100 |
10th | Aelix Therapeutics 2015, Barcelona (Spain), Series A | Developer of therapies for treating HIV | $12.6M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on HilleVax's competitors? Click to see the top ones
HilleVax's Investments and acquisitions
HilleVax has made no investments or acquisitions yet.
Reports related to HilleVax
Here is the latest report on HilleVax's sector:
View
News related to HilleVax
Media has covered HilleVax for a total of 14 events in the last 1 year, 4 of them have been about company updates and 2 about people movement.
鈥�
鈥�
GlobeNewswire鈥�May 08, 2025鈥�HilleVax
鈥�
GlobeNewswire鈥�Mar 29, 2025鈥�HilleVax
鈥�
GlobeNewswire鈥�Nov 07, 2024鈥�HilleVax
鈥�
鈥�
PR Newswire鈥�Aug 09, 2024鈥�, HilleVax
鈥�
GlobeNewswire鈥�Aug 09, 2024鈥�HilleVax
鈥�
Benzinga鈥�Aug 04, 2024鈥�, HilleVax
鈥�
鈥�
GlobeNewswire鈥�Aug 01, 2024鈥�HilleVax
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about HilleVax
Explore our recently published companies
- Cornish Cider Company - York based, 2018 founded, Funding Raised company
- ChemExpo India - Mumbai based, 2019 founded, Unfunded company
- Zarthi - Noida based, 2023 founded, Unfunded company
- GlobalGreen Insurance Agencies - Chesterfield based, 2006 founded, Unfunded company
- Astonbet - 2024 founded, Unfunded company
- dAIgnostiX - Bengaluru based, 2018 founded, Unfunded company
